据美国证券交易委员会的4表格文件显示， 狼人治疗公司 ( Werewolf Therapeutics, Inc.) (NASDAQ:HOWL)董事Luke Evnin于2026年1月16日出售了38,782股普通股。这些股票以加权平均价0.54美元出售，总价值为20,942美元。交易价格区间为0.535美元至0.5495美元。此次交易发生之际，HOWL股价接近其52周低点0.53美元，根据 ...
董事Luke Evnin报告在三天内出售了 Werewolf Therapeutics, Inc. (NASDAQ:HOWL) 的普通股，交易总额约为61,787美元。这些交易发生在2026年1月13日至1月15日期间，价格范围在0.55美元至0.57美元之间。根据 InvestingPro 数据，这家市值仅为2718万美元的微型生物技术公司在过去一年中股价下跌了超过60%。
11 天on MSN
Werewolf Therapeutics (HOWL) eyes 2026 catalysts following FDA guidance and encouraging ...
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, ...
The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果